{"disease":{"id":"resectable-esophageal-squamous-cell-carcinoma","name":"resectable esophageal squamous cell carcinoma"},"drugs":{"marketed":[{"drug_id":"tislelizumab","indication_name":"Unresectable or metastatic esophageal squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"tislelizumab","indication_name":"Unresectable or metastatic esophageal squamous cell carcinoma (ESCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"chembl-chembl1789844","indication_name":"Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic esophageal squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04848753","title":"Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":663,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT04187352","title":"A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":540,"lead_sponsor_name":"CStone Pharmaceuticals","has_results":false},{"nct_id":"NCT05043688","title":"Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":426,"lead_sponsor_name":"Zhigang Li","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05381636","title":"Esophageal Arterial Infusion Chemotherapy Versus Systemic Intravenous Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Prospective, Multicentre, Randomised Controlled Clinical Study","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT07530094","title":"Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"Ning Jiang, M.D./Ph.D.","has_results":false},{"nct_id":"NCT06472635","title":"a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":95,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT06475196","title":"Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":90,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT05522894","title":"AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04974047","title":"Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT07469241","title":"Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07457528","title":"Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT05833971","title":"Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Guangzhou Institute of Respiratory Disease","has_results":false},{"nct_id":"NCT07339488","title":"Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Chuangzhen Chen","has_results":false},{"nct_id":"NCT04533490","title":"A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT07112833","title":"A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Hebei Medical University Fourth Hospital","has_results":false},{"nct_id":"NCT06908382","title":"Neoadjuvant QL1706 Therapy for ESCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Shandong Provincial Hospital","has_results":false},{"nct_id":"NCT07435454","title":"Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"Jiangsu Cancer Institute & Hospital","has_results":false},{"nct_id":"NCT04391049","title":"Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":16,"lead_sponsor_name":"NRG Oncology","has_results":true},{"nct_id":"NCT04460937","title":"Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":21},"guidelines":[],"source":"Drug Landscape verified database"}